2 October 2026
Novartis bets up to $7.8 billion on a Chinese mRNA drug as pharma's China rush grows
Novartis will license an early-stage autoimmune treatment from China's Abogen Biosciences for $575 million upfront and up to $7.2 billion more in milestones.
Big drugmakers keep shopping in China, and Novartis just placed one of the largest orders yet. The Swiss company agreed to license an experimental autoimmune treatment from Abogen Biosciences in a deal worth up to $7.8 billion, Abogen said on Friday.
What happened
The drug is Abogen's lead program, an early-stage therapy based on messenger RNA (mRNA, the same basic technology behind some Covid vaccines). Novartis gets the global rights for $575 million upfront. The other $7.2 billion only gets paid if the drug hits agreed milestones, such as passing trials or reaching approval. Novartis also gets an exclusive option on other medicines Abogen builds on its RNA platform.
A license is not a takeover. Novartis buys rights to the medicine, not the company, and licenses can usually be ended if a drug disappoints. That flexibility is one reason this structure has become the standard way Western drugmakers tap Chinese research. For the Chinese side, the cash helps fund work on their own pipelines at home.
Why it matters
Many of the world's best-selling drugs lose patent protection in the early 2030s, which lets cheaper copies in. Drugmakers need new products to replace those sales, and China has become a major source. ING estimates China will supply about a third of all new molecules in global pharma pipelines in 2026, up from 4% in 2014, and expects Chinese outlicensing deals to top $250 billion in value this year.
Novartis has extra reason to restock. Its shares, usually steady, had their worst month since 1987 last month after several clinical trial setbacks. Noorult data puts its market value at about $272 billion, so the upfront payment is a small slice of the company, even if the full deal is not.
It is far from alone. In the past few weeks:
- Novo Nordisk licensed a once-weekly obesity pill from Hengrui Pharma for up to $2.6 billion.
- GSK agreed to buy a blood cancer drug from Chimagen Biosciences for up to $750 million.
- AstraZeneca teamed up with Summit Therapeutics to test cancer drugs together, including one first developed by China's Akeso.
What to watch
Headline values like these are ceilings, not checks already written. Watch how many of Abogen's milestones are actually reached, whether Novartis uses its option on more of Abogen's RNA medicines, and how many more of these licensing deals arrive before year-end. Novartis's financials are on its Noorult company page.
The companies in this story
Based on reporting by CNBC: Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion